Dr. Henricus de Koning on Screening in NSCLC

Henricus de Koning, MD
Published: Thursday, Aug 18, 2016


Henricus de Koning, MD, Professor of Public Health & Screening Evaluation in the Department of Public Health of the Erasmus Medical Center in the Netherlands, discusses screening in non-small cell lung cancer (NSCLC).
 
There was a large randomized controlled trial in the United States that demonstrated that screening resulted in positive outcomes for NSCLC. However, after receiving screening 24% of patients in the trial were referred for further investigation. This referral rate is too high for the European healthcare system, said de Koning.   
 
There are several European trials investigating if screening with less follow-up is effective. These trials look at the volume of the nodules in NSCLC. Patients with intermediate nodules are told to return in 3 months for an additional CT scan. This is a novel approach, that should be helpful in reducing the amount of referrals, said de Koning.
 

Henricus de Koning, MD, Professor of Public Health & Screening Evaluation in the Department of Public Health of the Erasmus Medical Center in the Netherlands, discusses screening in non-small cell lung cancer (NSCLC).
 
There was a large randomized controlled trial in the United States that demonstrated that screening resulted in positive outcomes for NSCLC. However, after receiving screening 24% of patients in the trial were referred for further investigation. This referral rate is too high for the European healthcare system, said de Koning.   
 
There are several European trials investigating if screening with less follow-up is effective. These trials look at the volume of the nodules in NSCLC. Patients with intermediate nodules are told to return in 3 months for an additional CT scan. This is a novel approach, that should be helpful in reducing the amount of referrals, said de Koning.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x